| Title | Analysis of Multiple Factors Related to Hematologic Toxicity Following (153)Sm-EDTMP Therapy. | | Author(s) | Liu H, Zhan H, Sun D, Xu W, Ye X, Zhang H, Zhao C, Bao C, He G, Yin F | | Institution | Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, People's Republic of China. | | Source | Cancer Biother Radiopharm 2007 Aug; 22(4):515-20. | | Abstract | Purpose:The aim of this study was to investigate the clinical factors related to hematologic toxicity caused by treatment with samarium-153 ethylenediaminetetramethylene phosphonic acid ((153)Sm-EDTMP). Materials and
Methods: A total of 206 secondary bone neoplasm patients treated with (153)Sm-EDTMP were analyzed retrospectively. Logistic regression (SPSS 10.0 for Windows; Chicago, IL) and correlation analysis were used to evaluate the factors concerned.
Results: Age, number of bone metastatic lesions, chemotherapy before treatment with (153)Sm-EDTMP, concurrence of radiotherapy, and times of repeated treatments with (153)Sm-EDTMP were determined by single factor analysis to be related to hematologic toxicity. Chemotherapy before treatment with (153)Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with (153)Sm-EDTMP were determined by multiple factor analysis to be related to hematologic toxicity.
Conclusions: Chemotherapy before treatment with (153)Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with (153)Sm-EDTMP are the main clinical factors related to hematologic toxicity caused by (153)Sm-EDTMP therapy. In patients with such factors, more attention might be paid to the change of blood cell counts after (153)Sm-EDTMP therapy. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 17803446 |
|
